Novartis Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Novartis stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.
View analyst ratings for Novartis or view top-rated stocks.

Wall Street analysts have given Novartis a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Novartis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Novartis saw a decrease in short interest in the month of July. As of July 15th, there was short interest totaling 5,720,000 shares, a decrease of 13.9% from the June 30th total of 6,640,000 shares. Based on an average daily trading volume, of 1,790,000 shares, the days-to-cover ratio is presently 3.2 days. Approximately 0.3% of the company's shares are short sold.
View Novartis' Short Interest.

Novartis is scheduled to release its next quarterly earnings announcement on Tuesday, October 26th 2021.
View our earnings forecast for Novartis.

Novartis AG (NYSE:NVS) released its quarterly earnings results on Tuesday, July, 20th. The company reported $1.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.14. The business had revenue of $12.96 billion for the quarter, compared to the consensus estimate of $12.41 billion. Novartis had a trailing twelve-month return on equity of 25.25% and a net margin of 17.83%. The firm's quarterly revenue was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.36 earnings per share.
View Novartis' earnings history.

Novartis' stock was trading at $82.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVS shares have increased by 12.5% and is now trading at $92.39.
View which stocks have been most impacted by COVID-19.

Novartis announced an annual dividend on Wednesday, January 27th. Investors of record on Friday, March 5th will be given a dividend of $3.3784 per share on Monday, March 15th. This represents a dividend yield of 2.2%. The ex-dividend date of this dividend is Thursday, March 4th. This is an increase from Novartis's previous annual dividend of $3.04.
View Novartis' dividend history.

Novartis pays an annual dividend of $2.08 per share and currently has a dividend yield of 2.26%. Novartis does not yet have a strong track record of dividend growth. The dividend payout ratio of Novartis is 36.17%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novartis will have a dividend payout ratio of 31.04% next year. This indicates that Novartis will be able to sustain or increase its dividend.
View Novartis' dividend history.

11 brokers have issued 12-month price targets for Novartis' stock. Their forecasts range from $105.00 to $112.00. On average, they anticipate Novartis' share price to reach $108.50 in the next twelve months. This suggests a possible upside of 17.4% from the stock's current price.
View analysts' price targets for Novartis or view top-rated stocks among Wall Street analysts.

938 employees have rated Novartis CEO Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among Novartis' employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Novartis include Johnson & Johnson (JNJ), Roche (RHHBY), Pfizer (PFE), Eli Lilly and (LLY), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), Sanofi (SNY), GlaxoSmithKline (GSK), CSL (CSLLY), Zoetis (ZTS) and Regeneron Pharmaceuticals (REGN).
View all of NVS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), The Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Novartis' stock is owned by many different retail and institutional investors. Top institutional investors include Manning & Napier Group LLC (0.08%), Bristol John W & Co. Inc. NY (0.03%), Gofen & Glossberg LLC IL (0.01%), Confluence Investment Management LLC (0.01%), Scout Investments Inc. (0.01%) and Cardinal Capital Management Inc. (0.01%).

NVS stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Investment Research & Advisory Group Inc., TCW Group Inc., Raymond James Trust N.A., Berkshire Bank, Bristol John W & Co. Inc. NY, Patten & Patten Inc. TN, and Minot Wealth Management LLC.

NVS stock was acquired by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Scout Investments Inc., Cardinal Capital Management Inc., Confluence Investment Management LLC, Brookstone Capital Management, Avalon Investment & Advisory, Old Port Advisors, and Ascent Wealth Partners LLC.

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVS stock can currently be purchased for approximately $92.39.

Novartis has a market capitalization of $211.45 billion and generates $48.66 billion in revenue each year. The company earns $8.07 billion in net income (profit) each year or $5.75 on an earnings per share basis.

Novartis employs 103,914 workers across the globe.

The following companies are subsidiares of Novartis: Admune Therapeutics, Advanced Accelerator Applications, Alcon, Amblyotech, AveXis, CellforCure, Chiron Corporation, CoStim Pharmaceuticals, Corthera, Encore Vision, Endocyte, Fougera Pharmaceuticals, Hexal, Novartis Inflammasome Research, Protez Pharmaceuticals, Selexys Pharmaceuticals Corporation, Spinifex Pharmaceuticals, The Medicines Company, Vedere Bio, Xiidra, and Ziarco.

Novartis was founded in 1996.

The official website for Novartis is www.novartis.com.

Novartis is headquartered at LICHTSTRASSE 35, BASEL V8, CH 4056.

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at (161) 324-1111 or via email at [email protected]